FlawCheck Citator
Check how courts have cited this case. Use our free citator for the most current treatment.
No. 8963981
United States Court of Appeals for the Ninth Circuit

Toner v. Lederle Laboratories

No. 8963981 · Decided October 26, 1987
No. 8963981 · Ninth Circuit · 1987 · FlawFinder last updated this page Apr. 2, 2026
Case Details
Court
United States Court of Appeals for the Ninth Circuit
Decided
October 26, 1987
Citation
No. 8963981
Disposition
See opinion text.
Full Opinion
ORDER Upon consideration of the parties submissions, it appears there are certain erroneous or ambiguous statements in the first opinion of the court in this matter, Toner v. Lederle Laboratories, 779 F.2d 1429 (9th Cir.1986). The opinion is amended by striking the last two sentences in the fifth paragraph, which state: “Because of this difficulty, at the time of Kevin Toner’s vaccination, the whole cell pertussis vaccine was the only pertussis vaccine licensed by the Food and Drug Administration (FDA) for use in the United States. It remains the only licensed vaccine today.” In lieu of those sentences, the following language is inserted: “At the time of Keven Toner’s vaccination, the whole cell pertussis vaccine was the only pertussis vaccine licensed by the Food and Drug Administration (FDA) and distributed in the United States.” The opinion is further amended by striking the last two sentences in the ninth paragraph, which state: “However, in 1972, a review panel within the Bureau of Biologies of the FDA refused to certify Tri-Solgen as “safe and effective” although it did so certify the whole cell vaccines. Because the FDA has refused to relicense Tri-Solgen or any other fractionated cell product, the manufacture and sale of such a vaccine by Lederle, or any other pharmaceutical company, would constitute a criminal offense under the Food, Drug and Cosmetic Act. See 21 U.S.C. §§ 331 (d), 333(a), 355(a) (1982).” In lieu of those sentences, the following language is inserted: “However, in 1972, a review panel within the Bureau of Biologies of the FDA refused to certify Tri-Solgen as “safe and effective” although it did so certify the whole cell vaccines. Thus, whole cell vaccine was the only pertussis vaccine marketed in the United States because the sole licensee of the fractionated vaccine had ceased production in 1975, and the FDA had declined to relicense TriSolgen or any other fractionated cell product at that time. The manufacture and sale of a vaccine by any pharmaceutical company other than a valid licensee constitutes a criminal offense under the *181 Food, Drug and Cosmetic Act. See 21 U.S.C. §§ 331 (d), 333(a), 355(a) (1982).”
Plain English Summary
ORDER Upon consideration of the parties submissions, it appears there are certain erroneous or ambiguous statements in the first opinion of the court in this matter, Toner v.
Key Points
Frequently Asked Questions
ORDER Upon consideration of the parties submissions, it appears there are certain erroneous or ambiguous statements in the first opinion of the court in this matter, Toner v.
FlawCheck shows no negative treatment for Toner v. Lederle Laboratories in the current circuit citation data.
This case was decided on October 26, 1987.
Use the citation No. 8963981 and verify it against the official reporter before filing.
Why Attorneys Choose FlawFinder

Why Attorneys Choose FlawFinder

Side-by-side with Westlaw and LexisNexis

Feature FlawFinder Westlaw LexisNexis
Monthly price$19 – $99$133 – $646$153 – $399
ContractNone1–3 year min1–6 year min
Hidden fees$0, alwaysUp to $469/search$25/mo + per-doc
FlawCheck citatorIncludedKeyCite ($$$)Shepard's ($$$)
Plain-English summaryIncludedNoNo
CancelOne clickTermination feesAccount friction
Related Cases

Full legal research for $19/month

All 50 states · Federal regulations · Case law · Police SOPs · AI analysis included · No contract

Continue Researching →